Biotechnology
Clover Biopharmaceuticals Completes Enrollment of Adult and Elderly Population in SPECTRA Global Phase 2/3 Clinical Trial for its COVID-19 Vaccine Candidate
* SPECTRA enrolled over 29,000 adult and elderly participants across four continents achieving high ethnic diversity and robust dataset of circulating strains * Release of vaccine efficacy data anticipated in Q3 2021 and will include sequencing data of SARS-CoV-2 variants of concern and varia...
2021-07-06 14:00
3198
Antengene Announces Acceptance of IND Application in China for the Phase II Clinical Trial of Single-Agent Selinexor for the Treatment of Myelofibrosis (MF)
SHANGHAI and HONG KONG, July 6, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncolo...
2021-07-06 08:00
4673
South-Korean biotech Y-Biologics and French mid-pharma Pierre Fabre enter into a worldwide exclusive license agreement in the highly innovative field of immuno-oncology
DAEJEON, South Korea and CASTRES, France, July 6, 2021 /PRNewswire/ -- The South Korean biotech company Y-Biologics and the French pharmaceutical group Pierre Fabre have entered into a license agreement granting worldwide exclusive rights toPierre Fabre to develop and commercialize a family of hum...
2021-07-06 07:00
5290
SINOMED announces a clinical collaboration with the National University of Ireland Galway to evaluate a non-invasive assessment method for stenting
TIANJIN, China, July 5, 2021 /PRNewswire/ -- SINOMED, a leading international medical device company, today announced that they have teamed up with the National University of Ireland Galway (NUI Galway) to conduct a clinical trial for a new assessment method for stenting. The trial will employ the...
2021-07-05 19:42
3235
Everest Medicines Announces that Spero Therapeutics Entered into Licensing Agreement with Pfizer Inc. for SPR206 in ex-U.S. and ex-Asia Territories
SHANGHAI, July 5, 2021 /PRNewswire/ -- Everest Medicines
2021-07-05 18:16
4823
Abbisko and Sperogenix Announce An Exclusive Agreement to Develop ABSK021 for ALS and Other Rare Neurological Diseases in Greater China
SHANGHAI, BEIJING, HONG KONG, July 5, 2021 /PRNewswire/ -- Sperogenix (Shanghai ) MedTech Co., Ltd. ("Sperogenix"), a subsidiary of Sperogenix Therapeutics (platform company for development and commercialization of rare diseases medications inChina), has entered into an exclusive licensing agreeme...
2021-07-05 08:51
2261
Korea National Institute of Health (KNIH) conducts field inspection of companies with mRNA technology
SEOUL, South Korea, July 1, 2021 /PRNewswire/ -- Korea National Institute of
Health (KNIH), Korea's top research center in the field of hygiene and medicine
(with Mr. Kwon Jun-Wook as President) conducted a field inspection of key
companies with mRNA technology.
2021-07-01 21:00
2383
InDevR Launches VaxArray Polio Kit for Faster, Multiplexed Vaccine Characterization
BOULDER, Colo., July 1, 2021 /PRNewswire/ -- InDevR, Inc., a life science tools company providing powerful analytical technologies to support the development and production of vaccines and biotherapeutics, announced commercial availability of its VaxArray® Polio D-antigen quantification kit for r...
2021-07-01 15:00
1731
Clover and Dynavax Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Clover's COVID-19 Vaccine Candidate
* Clover to procure CpG 1018 adjuvant from Dynavax for use in the commercial production of Clover's COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum) * Pending conditional regulatory approvals, Clover expects to commence product launch of SCB-2019 (CpG 1018/Alum) by the end of 2021 CHENGDU,...
2021-06-30 16:00
5758
Clover Announces Advance Purchase Agreement with Gavi for Over 400 Million Doses of Clover's COVID-19 Vaccine for the COVAX Facility
* Pending WHO EUL for its COVID-19 vaccine candidate, Clover is committed to providing 64 million doses in 2021 and Gavi has options for an additional 350 million doses in 2022 * Clover will receive a significant upfront payment, a payment upon positive Phase 2/3 data, potential payments upon...
2021-06-30 16:00
2904
OnCusp Therapeutics Commences Operations to Advance Innovative Oncology Therapies
NEW YORK, June 29, 2021 /PRNewswire/ -- OnCusp Therapeutics (or "OnCusp"), a global biopharmaceutical company focused on translating cutting-edge research assets into innovative oncology therapeutics, announced that it has officially commenced operations both inNew York and Shanghai. OnCusp succ...
2021-06-30 09:29
1766
Subcutaneously Injected PD-L1 Antibody Envafolimab (KN035) Obtained Its Second Orphan Drug Designation From The U.S. FDA
SUZHOU, China, June 30, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to envafolimab (KN035), a recombinant humanized PD-L1 single-domain antibody independently invented by Alphamab Onco...
2021-06-30 08:55
9376
GSK Singapore and Vir Biotechnology Announce Advance Purchase Agreement with the Government of Singapore for Monoclonal Antibody Sotrovimab (VIR-7831)
* GSK Singapore has signed an Advance Purchase Agreement with the Government ofSingapore for sotrovimab * Sotrovimab is currently undergoing review by the Singapore Health Sciences Authority (HSA) under the Pandemic Special Access Route (PSAR) for interim authorization * Announcement follow...
2021-06-30 06:30
3024
Hanmi Pharmaceutical finds new innovative potential for "Efpeglenatide"
SEOUL, South Korea, June 29, 2021 /PRNewswire/ -- Hanmi Pharmaceutical (hereinafter Hanmi) recently announced that its new, long-acting diabetes biologic drug, efpeglenatide, was shown to significantly reduce incidences of major adverse cardiovascular events (MACE) and kidney disease in the resul...
2021-06-29 21:00
2841
I-Mab Announces Upcoming Participation at July Conference
SHANGHAI and GAITHERSBURG, Md., June 29, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conference in July. D...
2021-06-29 20:00
8636
Medical Affairs Teams are Increasingly Turning to Patient-centric Analytics to Improve Clinical Outcomes
SANTA CLARA, Calif., June 29, 2021 /PRNewswire/ -- The shift to value-based care relies heavily on evidence-based medicine, and pharmaceutical companies play an important role in scientific communication across the healthcare ecosystem. Medical affairs experts interact with healthcare professiona...
2021-06-29 18:02
1439
Seegene unveils "MOBILE STATION," for on-site routine testing at public-use facilities and communities
* Seegene unveils "MOBILE STATION" at the Medlab Middle East 2021 * Mobile laboratory designed for mass testing at schools, airports, or communities, delivering test results within 3h 30min with the maximum testing capacity of 7,500 a day * The biotechnology firm to sign an MOU with G42 Heal...
2021-06-29 18:00
2147
BioVaxys Announces Non-Brokered Private Placement
VANCOUVER, BC, June 29, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) ("BioVaxys" or the "Company") is pleased to announce a non-brokered private placement (the "Private Placement") consisting of up to 9,090,909 units ("Units") at a price of$0.22 per Unit for to...
2021-06-29 10:46
5517
Innovent Announces License Agreement with Synaffix in an ADC Technology Deal
SAN FRANCISCO and SUZHOU, China, June 29, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2021-06-29 08:00
6190
Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2021
Added 19,367 New Subscribers in 4Q21 Revenues Up 0.8% YoY to RMB302.3 million ($46.1 million) Net Income Attributable Up 31.7% YoY to RMB127.7 million ($19.5 million) Operating Cash Flow Up 134.6% YoY to RMB211.1 million ($32.2 million) Conference Call to be Held on June 29, 2021 at 8:00 a.m. ET HO...
2021-06-29 04:16
23068
Week's Top Stories
Most Reposted
Never Miss a Message: Agoda's Customer Support Now Travels With You
[Picked up by 328 media titles]
2026-02-24 12:00
NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 311 media titles]
2026-02-23 08:00
HBX Group and Traveloka expand strategic partnership to deepen APAC supply and accelerate global distribution
[Picked up by 309 media titles]
2026-02-26 09:30
Amadeus acquires SkyLink to accelerate the deployment of AI in travel
[Picked up by 309 media titles]
2026-02-26 19:57
Klook and Osaka Convention & Tourism Bureau sign MoU to advance inbound tourism and foster socio-economic development throughout Osaka Prefecture
[Picked up by 302 media titles]
2026-02-24 16:13
Most Read
NYSE Content Update: AI Data Platform DDN Appoints Guido Torrini as Finance Chief
2026-02-24 22:08
4890
